Northrop Grumman

NOC

----

2026-W372026-09-07

NOC.US Weekly Report · 2026-W37

Northrop Grumman rose modestly 0.78% this week, closing at $518.97. Trading at a historically low valuation (P/E 16.4x at 31st percentile over three years), with strong institutional backing, yet facing divergent capital flows—both large and retail investors showed net outflows, creating a contrast with bullish analyst targets. Limited short-term buying support leaves medium-term upside dependent on earnings recovery and sustained macro tailwinds in defense spending.

Market Performance

Weekly close at $518.97 versus $514.98 (Sept. 4), up 0.78%. Intra-week high $523.01 and low $515.25 yielded a 1.51% range, reflecting subdued consolidation without directional thrust.

Cumulative volume approximately 3.44 million shares, relatively low. Turnover rate at 0.42%, well below typical levels, indicating muted trading interest and lack of breakout momentum.

Valuation and Earnings

Valuation Positioning: P/E 16.4x sits near historical lows. Against a three-year distribution, current valuation ranks at the 31.65th percentile—lower than 84.95% of historical levels—significantly below the industry median of 21.46. Relative value is compressed into the lower tail.

Latest Quarter: Q2 2026 EPS $7.68, down 25% from Q1 ($6.14) and down 5.77% year-over-year. Revenue $10.876 billion grew 5.07% YoY, but net profit declined 6.81% YoY, signaling margin compression.

Forward Guidance: Consensus expects 2026 full-year EPS of $29.26 (median). Q1 + Q2 cumulative $13.82 implies the back half must contribute $15.44, or ~$7.72 per quarter—roughly flat with current Q2 run-rate. No material recovery is priced into expectations.

Capital Flows and Institutional View

Fund Direction: Net outflows this week. Large cap net outflow $210.74, retail net outflow $279.62; only mid-cap showed minor inflow of $6.14. Institutional stepping-aside signals caution.

Analyst Ratings: 9 Buy, 10 Hold, 1 No Opinion, 4 Sell/Reduce across 24 total analysts. Median price target $648.05, implying ~25% upside from current $519. Ratings skew constructive on fundamentals, though near-term capital sentiment trails.

Weekly News Narrative

Key themes emerging from newsflow:

Advanced R&D Progress —— Testing quantum drone guidance systems, $7M DARPA contract for diamond-cooled chips, 500-hour F-16 electronic warfare flight milestones. R&D pipeline demonstrating depth in next-generation defense tech.
Management Confidence —— CEO Kathy Warden’s Morgan Stanley Laguna conference remarks reinforce conviction on long-term trajectory.
Macro Supply-Chain Backdrop —— Defense industrial consolidation, infrastructure expansion offsetting consumer softness. Structural tailwinds supporting sector growth.

Top News This Week (ranked by relevance):

Summary

Northrop exhibits a “deeply undervalued + positive targets + weak institutional buying” contradiction. P/E compression at three-year lows contrasts sharply with 9 Buy/10 Hold ratings and $648 median target, yet both large and retail capital pulled out this week—suggesting hesitation over near-term profit inflection. Q2 profit decline paired with modest 5% revenue growth signals earnings traction is still fragile.

The offsetting factor: R&D momentum across quantum systems, advanced chips, and electronic warfare electronics is genuine; macro defense spending tailwinds remain structural. The critical milestone is Q3 earnings and full-year guidance refinement. Capital returning to bids becomes the tell for whether this valuation reprieve persists or remains temporary.